98%
921
2 minutes
20
Background And Aims: HDV exploits HBV surface-protein (HBsAg) for entering into hepatocytes. HBsAg consists of 3 isoforms: Large- (L-HBs, predominantly present in virions and mediating binding to NTCP-receptor), Middle- (M-HBs) and Small-HBsAg (S-HBs). Here, we investigated the kinetics of HBs isoforms under bulevirtide treatment (BLV).
Methods: 67 consecutive patients with HDV-related compensated cirrhosis starting BLV 2 mg/day were enrolled. L-HBs, M-HBs and S-HBs were quantified by ad-hoc ELISAs in baseline and week 48 (W48) samples.
Results: At baseline, median (IQR) HDV-RNA was 5.1 (4.3-5.7) log IU/mL while median (IQR) S-HBs, M-HBs and L-HBs levels were 3801 (1401-7462), 743 (211-1710) and 5 (1-13) ng/mL. At W48, virological responses (VR) were observed in 72% (48/67) of patients, while 25.4% (17/67) achieved undetectable HDV-RNA (11/17 with ALT-normalisation). A decline of S-HBs, M-HBs and L-HBs levels was observed in 51%, 63% and 31% of patients (median [IQR] decline: 961 [461-1985], 258 [68-626] and 4 [2-12] ng/mL). Notably, patients with undetectable HDV-RNA at W48 had baseline L-HBs and S-HBs levels lower than patients not achieving this end-point (1 [0.3-7] vs. 6 [2-13] ng/mL, p = 0.04 and 1570 [369-5185] vs. 4015 [1646-8687] ng/mL, p = 0.002). By AUROC, patients with baseline L-HBs < 3 ng/mL or S-HBs < 3400 ng/mL were more likely to achieve HDV-RNA undetectability at W48 (39.3% vs. 15.8%, p = 0.04 and 38.7% vs. 13.9%, p = 0.03). Furthermore, the combination of pre-treatment L-HBs < 3 ng/mL + HDV-RNA < 5logIU/mL and S-HBs < 3400 ng/mL + HDV-RNA < 5logIU/mL was the best predictor for achieving undetectable HDV-RNA at W48 (56.3% vs. 15.7%, p = 0.002 and 60% vs. 11%, p < 0.001).
Conclusions: Quantification of L-HBs and of S-HBs, along with HDV-RNA, may reflect the burden of circulating infectious virions in HBV/HDV co-infection, providing a promising tool to identify patients more likely to respond to BLV.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/liv.70094 | DOI Listing |
J Occup Med Toxicol
September 2025
Occupational Medicine, Antioch Medical Center, Kaiser Permanente, 4501 Sand Creek Road, Antioch, CA, 94531, USA.
Background: This study examines trends in delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) positivity rates in pre-employment urine drug screenings at a single university-based hospital occupational medicine clinic from 2017 to 2022, following California's recreational cannabis legalization in 2016, with sales beginning officially on January 1, 2018.
Methods: Retrospective analysis of 21,546 de-identified urine drug screenings from 2017 to 2022 was conducted. Initial screening used instant urine drug immunoassays (50 ng/mL cutoff for THC-COOH), followed by confirmatory gas chromatography-mass spectrometry (15 ng/mL cutoff).
Acta Ortop Mex
September 2025
Sector de Ortopedia Infantil, Instituto de Ortopedia y Traumatología «Carlos E. Ottolenghi», Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos Aires, Argentina.
Introduction: medial patellofemoral ligament (MPFL) reconstruction using an autologous quadriceps tendon graft to treat patellofemoral dislocation in the pediatric population is a surgical alternative that may offer advantages compared to other types of grafts. We assessed clinical and functional outcomes, rate of return to sport, and complications in a cohort of pediatric patients.
Material And Methods: retrospective and descriptive cohort study.
Cont Lens Anterior Eye
September 2025
Keele University, Stafforshire, UK.
Purpose: To investigate associations between dry eye disease (DED) symptoms and psychological distress (depression, anxiety, stress) among undergraduate health sciences and nursing students in the Gaza Strip during the 2023-2025 conflict period.
Methods: A cross-sectional study used convenience sampling via WhatsApp and face-to-face interviews between 4 February and 29 April 2025. Participants completed a demographic form, the Arabic Ocular Surface Disease Index (OSDI), and the Arabic Depression Anxiety Stress Scale-8 (DASS-8).
Acad Radiol
September 2025
Department of Radiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China (M.W., Z.Z., K.D., S.L., Y.L., F.G., M.G.). Electronic address:
Rationale And Objectives: To investigate the performance of CT-guided percutaneous CNB for the diagnosis of pancreatic tumors using a blunt-tip needle technique.
Materials And Methods: This is a retrospective cohort study included 103 consecutive patients (64 males and 39 females; mean age 61±12.3 years;range 21-86) who underwent CT-guided percutaneous CNB of pancreatic lesions using a blunt-tip needle technique between October 2021 and October 2023.
Diabet Med
September 2025
Endocrinology Department, East Surrey Hospital, Surrey and Sussex Healthcare NHS Trust, Redhill, UK.
Aim: To explore the experiences of patients, families and clinicians managing steroid-induced hyperglycaemia (SIH) out of the hospital and identify areas for improved care.
Methods: We searched hospital records to identify patients requiring input from the diabetes inpatient team between February 2022 and March 2023 due to steroid usage. Clinicians, patients and their family members were interviewed remotely about their experiences of care and views on how to improve it.